Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JFitnich who wrote (6965)	8/23/2002 3:24:24 PM
From: Biomaven	Read Replies (1) of 52153

This is good news for the overall market (except for brokers): NEW YORK, Aug 23 (Reuters) - Borrowings by investors from New York Stock Exchange member firms to buy stocks, or margin debt, fell in July for the third straight month to the lowest level since October 1998, according to the Big Board. Margin debt fell 7 percent in July to $136.2 billion from the $146.27 billion in June, said the NYSE. July was a dismal month for U.S. stocks, with the Standard & Poor's 500 (INDEX:$SPX.X) shedding 7.9 percent and the Nasdaq Composite Index (INDEX:$COMPX) falling 9.2 percent. Margin debt has decreased by more than half from its record level - $278.5 billion - of March 2000, when technology and Internet stocks peaked. Trading on margin is a practice that allows a buyer to put down a percentage of the purchase price and use the stock being bought as collateral. When a stock falls far enough, a margin investor must either deposit more cash into his account or liquidate the stock. Equity market investors with margin accounts can typically borrow up to 50 percent of their positions to finance the purchase of stocks or for other expenditures. Copyright 2002, Reuters News Service

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next